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external data using Bayesian MCMC methods. Economic analysis was undertaken
using 1) standard cost-utility decision rules within each topic, and 2) constrained
optimisation across all modelled topics. RESULTS: The guideline included fifteen
individual economic evaluation topics. Under usual processes, piecewise economic
modelling would have been used to evaluate between one and three guideline
topics. The Whole Disease Model provided a consistent platform for the economic
evaluation of eleven of the fifteen guideline topics, ranging from alternative diag-
nostic technologies through to cytotoxic treatments for metastatic disease. The
constrained optimisation analysis identified a configuration of colorectal services
which was expected to maximise QALY gains without exceeding current expendi-
ture levels. CONCLUSIONS: This study demonstrates that Whole Disease Model-
ling is feasible and can allow for the economic analysis of virtually any intervention
across a disease service within a consistent conceptual and mathematical infra-
structure. The approach may be especially valuable in instances whereby a sub-
stantial proportion of a disease service has not previously been subjected to eco-
nomic evaluation.
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OBJECTIVES: To study the association between Diabetes Mellitus (DM) and the
incidence of Cancer, focusing on type-specific and sex-specific cancers.METHODS:
Study’s data were obtained from CSD LPD, an Italian General Practitioner’s longi-
tudinal database. We have evaluated the risk of Cancer incidence among people
with DM compared with those without this pathology, in patients who had no
reported history of Cancer at the start of the follow-up on January 2006. For the DM
group, patients with at least one diagnosis of DM and a GP contact from January -
December 2005 have been selected, while for the DM free group, patients without a
diagnosis of DM and a contact with the GPs in the same period have been selected.
Both groups have been followed-up for 5 years. In order to evaluate an association
between the presence of DM and the incidence of Cancer multivariate logistic
models adjusted by age and sex have been implemented. RESULTS: A total of
73.144 (6 %) patients with a diagnosis of DM and 1.119.652 (94%) patients without
DM diagnosis were selected. During follow-up 8.824 and 82.477 incident cases of
Cancer were documented from the DM and DM free groups respectively. Statistical
analysis showed an Adjusted (age and sex) Odds Ratio of 1,06 (95% Cl 1,06-1,20)
suggesting that patients with DM have a 6% increased risk of cancer incidence (all
types). Regarding type-specific cancer analysis the OR for Liver cancer (2,44 [95% Cl
2,11-2,82]) and Pancreas cancer (2,27 [95% Cl 1,95-2,66]) were higher for DM pa-
tients. Regarding sex-specific cancers, the risk of Uterine body cancer was higher
for diabetic women (1,52 [95% Cl 1,17-1,99]), while in men DM seems to have a
protective effect, for example in Prostate cancer (0,86 [95% Cl 0,79-0,95]).
CONCLUSIONS: Patients with DM may be at increased risk of total, site-specific and
sex-specific cancer.
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OBJECTIVES: Simulation models are an essential tool in estimating the impact of
vaccination, screening and treatment on cancer rates. Model calibration is the
process of identifying reasonable values for model parameters, such that the out-
puts of the model are close to values observed in a real population. The purpose of
this work was to calibrate an existing model for cervical cancer using Irish data and
Markov Chain Monte Carlo (MCMC) in a Bayesian framework. This is compared and
contrasted with a previous random search calibration. METHODS: An existing mi-
crosimulation model for cervical disease which was coded in C was embedded in a
loop running in R. MCMC, which is an iterative algorithm was implemented in
parallel on multiple desktop machines and the results were collated for analysis.
The calibration method used differs from pure optimisation strategies and identi-
fies a probability distribution on the parameter space, which is of benefit for models
requiring probabilistic sensitivity analysis. RESULTS: Estimates of the model pa-
rameters were obtained from both MCMC and from the fitting of existing reference
parameter sets resulting from a random search of the parameter space. These are
compared on the basis of goodness of fit statistics (the sum of squared errors
between targets and fitted values). Of 20 MCMC chains that were run, 5 of them
gave better fits than the best fit sets for the random search method. However, 8 of
the 20 chains had not reached parameter sets that gave good fits when compared
with the best 135 fitted sets from the random search method. CONCLUSIONS:
MCMC is a useful technique which provides probabilistic estimates of the param-
eters of interest in a calibration exercise. Care is needed with starting values and
proposal distributions to ensure that the chains have converged and that the pa-
rameter space is properly explored.
PCN196
REVIEW OF COST EFFECTIVENESS OF TRASTUZUMAB IN EARLY BREAST
CANCER
Van rooijen EM1, Krol M2
1institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands, 2Erasmus
University, Rotterdam, The Netherlands
OBJECTIVES: The treatment of breast cancer is associated with high costs, influ-
enced by the introduction of more effective but expensive drugs, such as trastu-
zumab. This study aims to review cost-effectiveness studies of trastuzumab in the
adjuvant setting of early breast cancer and to explore the relation between (meth-
odological) differences in study design and cost-effectiveness outcomes.
METHODS:A systematic review was performed to identify cost-effectiveness stud-
ies of trastuzumab published between January 1998 and March 2011. All costs were
converted to 2009 Euros. Sources of variation in study design were identified and
divided into three categories: 1) methodological factors prescribed by national
guidelines; and 2) intrinsic factors, such as methodological or practical choices
made by the principal researchers; 3) extrinsic factors, such as the price of
trastuzumab. RESULTS: Fourteen cost-effectiveness studies were identified of
which one was a meta-analysis integrating data of multiple clinical trials. All were
modelling studies. ICERs of chemotherapy trastuzumab vs. chemotherapy alone
ranged from being the dominant strategy to € 87.889/QALY gained. The level of
detail presented regarding study design and outcomes differed strongly, hamper-
ing the identification of factors influencing this wide range of outcomes. However,
of the mutually presented aspects, especially the treatment regimen of the under-
lying clinical trial seemed to influence outcomes. Variation among studies using
the same clinical trial appeared related to methodological factors prescribed by
national guidelines, such as perspective and time horizon, intrinsic factors, such as
assumed duration of benefit and extrinsic factors, e.g. country specific practice
variation. CONCLUSIONS: Cost-effectiveness levels of trastuzumab differed
strongly, even between modelling studies based on the same clinical trial. Out-
comes were influenced by methodological aspects such as time horizon chosen
and assumed duration of benefit. A higher level of detail presented in the articles is
needed to increase insight in causes of variation in cost-effectiveness outcomes.
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OBJECTIVES: To assess the health related quality of life (HRQoL) in the growing
group of long term lymphoma survivors with preference based instruments.
METHODS: Population based cross-sectional data was collected in patients diag-
nosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (N778).
HRQoL was measured using both a generic and a disease specific preference-based
instrument, the EQ-5D 5-level and a time-trade-off valued version of the EORTC
QLQ-C30. RESULTS: On average patients with HL or NHL were diagnosed 4.35[SD
2.56] years prior to the study. Mean QoL was 0.83 using EQ-5D [SD .16, Range -.11
- 1.0] and 0.88 using QLQ-C30 [SD .10 Range .38 - 1.0]. Mean EQ-5D score for
lymphoma survivors is significantly lower than the average HRQoL found in the
Dutch population (p0.001). However, mean QLQ-C30 score for lymphoma survi-
vors did not differ from the Dutch population. Regression analysis identified a
significant lower HRQoL with having active disease (measured by treatment activ-
ity) and comorbidities depression, high blood pressure, respiratory diseases, osteo-
arthritis, and back-pain. Age, type of lymphoma, and time passed since diagnosis
did not affect HRQoL. The discrepancy between EQ-5D and QLQ-C30 in deviation
from the Dutch population is likely to be caused by better discrimination of worse
health states in the EQ-5D. CONCLUSIONS: The average HRQoL in long-term lym-
phoma survivors seems relatively high, especially when measured by the QLQ-C30.
However, subgroup analyses revealed HRQoL was affected by active disease and
comorbidities, other than, but perhaps related to, cancer. This has two important
implications. Firstly, population-based studies need to incorporate comorbidities
to adequately assess and forecast HRQoL in lymphoma survivors. Secondly, in
economic evaluations the modelling of cancer free survival needs to be reconsid-
ered since HRQoL in life years gained is affected by comorbidities. Future economic
evaluations should incorporate these two implications to obtain more accurate
HRQoL estimates.
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OBJECTIVES: A systematic review of the economical assessment studies on
genomics and proteomics in the field of oncology. Our aim is to analyze those
emerging diagnostic and therapeutic technologies whose cost effectiveness ratio
make them suitable for its adoption in the different health systems from a social
point of view.METHODS:We locate the most relevant studies in the last 10 years in
Medline, Embase, Cancerlit, Cochrane Library databases and we analyze the re-
sults. The following keywords were used: genetic screening, gene, pharmacog-
enomics, proteonomics, microarrays, biochips, cost analysis, cost effectiveness,
cost benefit, cost minimization, neoplasm, tumour and cancer. RESULTS: We an-
alyze 13 studies from which 5 assess aspects about breast cancer, 7 about colorectal
neoplasm, and 1 about urologic pathology. From these analyzed studies, 4 were
cost utility studies, 8 were cost effectiveness studies, and one was a cost minimi-
zation study. CONCLUSIONS:We highlight the increase of economical assessment
studies on genomics and proteomics, constituting an invaluable help for the san-
itary and medical decision makers over the suitability and relevance of incorporat-
ing the contributions of genomics and proteomics in the field of oncology, intro-
ducing the specific ethical and social aspects of this specialty.
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